FMR1 and fragile X syndrome: In an alternative strategy, CRISPR/Cas9 was used to correct the genetic cause of FXS by excising the expanded CGG repeat in human FXS iPS cells, causing a reactivation in FMRP expression in 20% of isolated colonies (Xie, et al., 2016).